Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
Zheng X, Zhang L, Wu L, Zhao J, Sun J, Fang Y, Zhou J, Chu Q, Shen Y, Yang Z, Chen L, Huang M, Lin X, Liu Z, Shen P, Wang Z, Wang X, Wang H, Han Z, Liu A, Zhang H, Ye F, Gao W, Wu F, Song Z, Chen S, Zhou C, Wang Q, Xu C, Huang D, Zheng X, Miao Q, Jiang K, Xu Y, Wu S, Wang H, Zhang Q, Yang S, Li Y, Chen S, Lin G. Zheng X, et al. Among authors: liu z, liu a. BMC Cancer. 2023 Dec 16;23(1):1244. doi: 10.1186/s12885-023-11737-x. BMC Cancer. 2023. PMID: 38104105 Free PMC article.
[A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].
Xu YJ, Zhu WG, Liao ZX, Kong Y, Wang WW, Li JC, Huang R, He H, Yang XM, Liu LP, Sun ZW, He HJ, Bao Y, Zeng M, Pu J, Hu WY, Ma J, Jiang H, Liu ZG, Zhuang TT, Tan BX, Du XH, Qiu GQ, Zhou X, Ji YL, Hu X, Wang J, Ma HL, Zheng X, Huang J, Liu AW, Liang XD, Tao H, Zhou JY, Liu Y, Chen M. Xu YJ, et al. Among authors: liu y, liu lp, liu aw, liu zg. Zhonghua Yi Xue Za Zhi. 2020 Jun 16;100(23):1783-1788. doi: 10.3760/cma.j.cn112137-20200303-00574. Zhonghua Yi Xue Za Zhi. 2020. PMID: 32536123 Clinical Trial. Chinese.
Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
Ai X, Cui J, Zhang J, Chen R, Lin W, Xie C, Liu A, Zhang J, Yang W, Hu X, Hu X, Zhao Q, Rao C, Zang YS, Ning R, Li P, Chang L, Yi X, Lu S. Ai X, et al. Among authors: liu a. Clin Cancer Res. 2021 Feb 1;27(3):704-712. doi: 10.1158/1078-0432.CCR-20-3063. Epub 2020 Nov 13. Clin Cancer Res. 2021. PMID: 33188140
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, Zhang X, Dong X, He J, Li X, Chen G, Li X, Zhang H, Liao W, Zhang Y, Ma Z, Jiang L, Cui J, Hu C, Wang W, Huang C, Zhao J, Ding C, Hu X, Wang K, Gao B, Song Y, Liu X, Xiong J, Liu A, Li J, Liu Z, Li Y, Wang M, Zhang B, Zhang D, Lu S. Ai X, et al. Among authors: liu z, liu x, liu c, liu a. J Thorac Oncol. 2021 Aug;16(8):1403-1414. doi: 10.1016/j.jtho.2021.04.001. Epub 2021 Apr 26. J Thorac Oncol. 2021. PMID: 33915252 Free article. Clinical Trial.
10,824 results
You have reached the last available page of results. Please see the User Guide for more information.